An Integrated Management Paradigm for Skull Base Chordoma Based on Clinical and Molecular Characteristics

Abstract

Objective Previous work categorized skull base chordoma (SBC) into three genetic risk groups based on 1p36 and homozygous 9p21(p16) deletions, accounting for a wide variability in prognosis (A = low-risk, B = intermediate-risk, C = high-risk). However, it remains unclear how these groups could guide management.

Study Design By integrating surgical outcome and adjuvant radiation (AdjXRT) information with genetic data on 152 tumors, we sought to develop an evidence-based management algorithm for SBC.

Results Gross total resections (GTRs) were associated with improved progression free survival (PFS) in all genetic groups. For Group C tumors, GTR and AdjXRT independently contributed to PFS (multivariate Cox proportional hazard ratio [HR] = 0.14, p = 0.002, and HR = 0.40, p = 0.047, respectively). For Group B tumors, AdjXRT improved outcomes only when GTR was not feasible (log-rank p = 0.008), but not following GTR (log-rank p = 0.54). However, 24 of 25 Group A tumors underwent GTR, and AdjXRT for these did not confer any benefit (log-Rank p = 0.285). The high GTR rates in Group A could be explained by smaller tumor sizes (mean = 0.98cc/4.08cc/4.92cc for Group A/B/C, respectively, p = 0.031) and lack of invasiveness. Group A tumors were also more frequently diagnosed in young people (p = 0.002) as asymptomatic lesions (p = 0.001), suggesting that they could be precursors to tumors in higher risk groups.

Conclusion Genotypic grouping by 1p36 and homozygous 9p21(p16) deletions can predict prognosis in SBC and guide management. GTR remains the cornerstone of SBC treatment and can be sufficient without AdjXRT in low and intermediate risk tumors. Low-risk tumors are associated with a less invasive phenotype, which makes them more amenable to GTR.

Keywords

chordoma - clival chordoma - skull base - genetics - fluorescent in situ hybridization - radiotherapy

Publikationsverlauf

Eingereicht: 11. Februar 2021

Angenommen: 23. April 2021

Artikel online veröffentlicht:
22. Juni 2021

• References

• 1 McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 2001; 12 (01) 1-11
• 2 Chambers KJ, Lin DT, Meier J, Remenschneider A, Herr M, Gray ST. Incidence and survival patterns of cranial chordoma in the United States. Laryngoscope 2014; 124 (05) 1097-1102
• 3 Smoll NR, Gautschi OP, Radovanovic I, Schaller K, Weber DC. Incidence and relative survival of chordomas: the standardized mortality ratio and the impact of chordomas on a population. Cancer 2013; 119 (11) 2029-2037
• 4 Jones PS, Aghi MK, Muzikansky A, Shih HA, Barker II FG, Curry Jr WT. Outcomes and patterns of care in adult skull base chordomas from the Surveillance, Epidemiology, and End Results (SEER) database. J Clin Neurosci 2014; 21 (09) 1490-1496
• 5 WHO. Soft Tissue and Bone Tumours, WHO Classification of Tumours, 5th Edition, Volume 3. Lyon, France: IARC Press; 2020
• 6 Bohman LE, Koch M, Bailey RL, Alonso-Basanta M, Lee JY. Skull base chordoma and chondrosarcoma: influence of clinical and demographic factors on prognosis: a SEER analysis. World Neurosurg 2014; 82 (05) 806-814
• 7 Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT, Ferreira MJ. Chordoma: current concepts, management, and future directions. Lancet Oncol 2012; 13 (02) e69-e76
• 8 Diaz RJ, Cusimano MD. The biological basis for modern treatment of chordoma. J Neurooncol 2011; 104 (02) 411-422
• 9 Stacchiotti S, Sommer J. Chordoma Global Consensus Group. Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol 2015; 16 (02) e71-e83
• 10 Yaniv D, Soudry E, Strenov Y, Cohen MA, Mizrachi A. Skull base chordomas review of current treatment paradigms. World J Otorhinolaryngol Head Neck Surg 2020; 6 (02) 125-131
• 11 Koutourousiou M, Gardner PA, Tormenti MJ. et al. Endoscopic endonasal approach for resection of cranial base chordomas: outcomes and learning curve. Neurosurgery 2012; 71 (03) 614-624 , discussion 624–625
• 12 Alahmari M, Temel Y. Skull base chordoma treated with proton therapy: a systematic review. Surg Neurol Int 2019; 10: 96
• 13 Zenonos GA, Fernandez-Miranda JC, Mukherjee D. et al. Prospective validation of a molecular prognostication panel for clival chordoma. J Neurosurg 2018; 1-10
• 14 Wang EW, Zanation AM, Gardner PA. et al. ICAR: endoscopic skull-base surgery. Int Forum Allergy Rhinol 2019; 9 (S3): S145-S365
• 15 Zenonos GAAK, Koutourousiou M, Zwagerman NT, Panczykowski D, Wang EW. Endoscopic endonasal approach for clival chordomas: 12 years of experience from a large skull base referral center. J Neurol Surg B Skull Base 2016; 77: A007